KOL Pulse

HARMONi-2 - FREE ACCESS

The HARMONi-2 clinical trial results, focusing on ivonescimab versus pembrolizumab in first-line treatment for PD-L1 positive NSCLC, have generated substantial discussion in the oncology community, particularly on social media. Below is an assessment based on various tweets and their context, evaluating the level of hype on a scale of 1 to 10.

TROPION-Lung01 - FREE ACCESS

The TROPION-Lung01 trial is a phase 3 trial of Datopotamab Deruxtecan (DatoDXD) vs docetaxel in the pretreated setting for the treatment of NSCLC. The clinical trial sponsors AstraZeneca and Daiichi Sankyo chose a fairly aggressive PR strategy as they rolled out their media communications at #ASCO24 , for a data presentation at #WCLC24.

ADAURA - FREE ACCESS

Sentiment from key opinion leaders regarding ADAURA trial presented at #ASCO23 by Dr. Roy Herbst from Yale. The ADAURA trial demonstrated that adjuvant treatment with osimertinib (Tagrisso) significantly improved disease-free survival in patients with resected EGFR-mutated non-small cell lung cancer.

ALINA

The ALINA trial is a Phase III study comparing adjuvant alectinib (Alecensa) versus chemotherapy in early-stage resected ALK-positive NSCLC. Presented by Dr. Ben Solomon at #ESMO23, the ALINA trial demonstrated a significant improvement in disease free survival for patients receiving alectinib over chemotherapy.

APPLE

The Phase II APPLE trial, led by Dr. Jordi Remon from CIOCC Barcelona, evaluates the appropriate sequencing of therapies osimertinib (Tagrisso) and gefitnib (Iressa) in EGRF-Mutant advanced non-small cell lung cancer (NSCLC) in a three arm trial design.

CheckMate 816

The FDA approved nivolumab + ipilimumab as neoadjuvant therapy for resectable non-small cell lung cancer, based on the results of the PHASE III CheckMate-816 clinical trial led by Dr. Patrick Forde of Johns Hopkins University and Dr. Jonathan Spicer of McGill University.

CONTACT-01

CONTACT-01 is a Phase III clinical trial of atezolizumab (Tecentric) + cabozantinib (Cabometyx) vs docetaxel monotherapy in patients with metastatic NSCLS perviously treated with checkpoint inhibitors and chemotherapy. The combination arm did not improve overall survival and was more toxic.

FLAURA2

FLAURA2, led by Dr. Pasi Janne from Dana Farber Cancer Institute, is a Phase III clinical trial of osimertinib (Tagrisso) with or without chemotherapy in EGFR-mutated advanced non-small cell lung cancer. Based on the results of the FLAURA2 clinical trial, Tagrisso received an additional FDA approval.

KEYNOTE-671

KEYNOTE-671, led by Dr. Heather Wakelee from Stanford University, is a randomized, double-blind, phase 3 trial to evaluate perioperative pembrolizumab (Keytruda) in patients with early-stage non-small cell lung cancer. The results of the KEYNOTE-671 clinical trial lead to an additional FDA approval for Keytruda.

LAURA

The LAURA trial demonstrated an improvement in progression-free survival (PFS) for patients with unresectable, stage III EGFR-mutated NSCLC when treated with osimertinib post-chemoradiation. The LAURA trial is led by Dr. Suresh Ramalingam from Winship Cancer Institute of Emory University.

LUNAR

LUNAR is a randomized, open-label, Phase III study, led by Dr. Ticiana Leal from Winship Cancer Institute at Emory University. LUNAR evaluated tumor treating fields (TTFields) with standard of care for the treatment of stage 4 non-small cell lung cancer (NSCLC) following platinum failure.

PAPILLON

PAILLON is a phase III, randomized clinical trial evaluating amivantamab (Rybrevant) plus chemotherapy in non-small cell lung cancer (NSCLC) with EGFR Exon 20 insertions. The FDA granted an approval to Rybrevant based on the PAPILLON clinical trial. Dr. Nicolas Girard was the presenting author at #ESMO23.

PACIFIC-2

The PACIFIC-2 trial is a phase III, randomized, double-blind, placebo-controlled, multi-centre international study of durvalumab (Imfinzi) concurrently adminstered with platinum-based CRT in patients with unresectable, stage III NSCLC.

Lung Cancer Clinical Trial Sentiment